, Volume 2, Issue 2, pp 361–371

Neuroimaging and therapeutics in movement disorders


DOI: 10.1602/neurorx.2.2.361

Cite this article as:
Eckert, T. & Eidelberg, D. Neurotherapeutics (2005) 2: 361. doi:10.1602/neurorx.2.2.361


In this review, we discuss the role of neuroimaging in assessing treatment options for movement disorders, particularly Parkinson’s disease (PD). Imaging methods to assess dopaminergic function have recently been applied in trials of potential neuroprotective agents. Other imaging methods using regional metabolism and/or cerebral perfusion have been recently introduced to quantify the modulation of network activity as an objective marker of the treatment response. Both imaging strategies have provided novel insights into the mechanisms underlying a variety of pharmacological and stereotaxic surgical treatment strategies for PD and other movement disorders.

Key Words

Movement disordersParkinson’s diseaseHuntington’s diseaseTourette’s syndromedystoniapositron emission tomography (PET)magnetic resonance imaging (MRI)
Download to read the full article text

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc 2005

Authors and Affiliations

  1. 1.Department of Neurology II and PsychiatryUniversity of MagdeburgGermany
  2. 2.Center for Neurosciences, Institute for Medical ResearchNorth Shore-Long Island Jewish Health SystemManhasset
  3. 3.Department of NeurologyNew York University School of MedicineNew York